semaglutide cardiovascular outcomes 2025 news today Wegovy lowers risk for adults with obesity at risk for heart disease Diabetes drugs semaglutide and tirzepatide

GLP-1s can induce nausea or digestive disturbances, potentially muddying the recovery waters

This approach can reduce the intensity of common side effects like bloating , constipation , and nausea while still providing metabolic benefits

The translational regulator FMRP controls lipid and glucose metabolism in mice and humans

Comparative efficacy of glucagon-like peptide 1 receptor agonists for cardiovascular outcomes in asian versus white populations: systematic review and meta-analysis of randomized trials of populations with or without type 2 diabetes and/or overweight or obesity

Beyond its pivotal role in height development during childhood and adolescence, GH continues to exert influence throughout adulthood, contributing to the maintenance of bone density, muscle mass, and overall organ health